Sotera Health to Acquire BioScience Laboratories to Expand its Antimicrobial and Antiviral Testing Capabilities
The acquisition will expand the antimicrobial and antiviral testing capabilities of Sotera’s Nelson Labs business in the US.
Sotera Health, a US-based provider of sterilization, lab-testing, and advisory services, announced on March 10, 2021 that it has acquired BioScience Laboratories, a topical antimicrobial product testing company located in the US.
The acquisition will expand the antimicrobial and antiviral testing capabilities of Sotera’s Nelson Labs business in the US, Sotera said in a company press release. Financial details of the acquisition were not disclosed.
“BioScience Laboratories is premier provider of antimicrobial testing services; known for its testing of consumer hand sanitizers, pre-operating hand-wash, and hard surface disinfectants. It is also recognized for its strong relationships with its customers and regulators,” said Michael B. Petras Jr., chairman and CEO of Sotera Health, in the press release. “This acquisition will expand and further strengthen our antimicrobial and virology lab testing capabilities. We welcome BioScience Laboratories’ strong management and expert staff as they join us in our mission, safeguarding global health.”
Source: Sotera
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
